Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 19 citing articles:

Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons
Michael G. Ison, Alberto Papi, Eugene Athan, et al.
Clinical Infectious Diseases (2024) Vol. 78, Iss. 6, pp. 1732-1744
Open Access | Times Cited: 50
Characteristics of the First Italian Older Adults Vaccinated with an Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine
Alexander Domnich, Andrea Orsi, Piero Luigi Lai, et al.
Medicina (2025) Vol. 61, Iss. 1, pp. 67-67
Open Access | Times Cited: 1
Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion F Protein Vaccine when Co-administered with Adjuvanted Seasonal Quadrivalent Influenza Vaccine in Older Adults: A Phase 3 Randomized Trial
Rebecca A. Clark, S. T. Davies, Jorge Labrador, et al.
Clinical Infectious Diseases (2024) Vol. 79, Iss. 4, pp. 1088-1098
Open Access | Times Cited: 7
Randomized, Open-Label Phase 3 Study Evaluating Immunogenicity, Safety, and Reactogenicity of RSVPreF3 OA Coadministered with FLU-QIV-HD in Adults Aged ≥ 65
Robert Buynak, Kevin D. Cannon, David DeAtkine, et al.
Infectious Diseases and Therapy (2024) Vol. 13, Iss. 8, pp. 1789-1805
Open Access | Times Cited: 5
The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access
Jonne Terstappen, Sarah F Hak, Anant Bhan, et al.
The Lancet Infectious Diseases (2024) Vol. 24, Iss. 12, pp. e747-e761
Closed Access | Times Cited: 5
RSVPreF3 OA respiratory syncytial virus vaccine in older adults: a profile of its use
Matt Shirley
Drugs & Therapy Perspectives (2025)
Open Access
Adult vaccinations against respiratory infections
Antoní Torres, Catia Cillóniz, Marta Aldea, et al.
Expert Review of Anti-infective Therapy (2025)
Closed Access
Respiratory syncytial virus vaccination in older adults and patients with chronic disorders: A position paper from the Portuguese Society of Pulmonology, the Portuguese Association of General and Family Medicine, the Portuguese Society of Cardiology, the Portuguese Society of Infectious Diseases and Clinical Microbiology, the Portuguese Society of Endocrinology, Diabetes and Metabolism, and the Portuguese Society of Internal Medicine
Tiago M. Alfaro, Filipe Froes, Cláudia Vicente, et al.
Pulmonology (2025) Vol. 31, Iss. 1
Open Access
Wege für bessere Impfraten
Jürgen Floege, T.F. Schwarz, Christoph Wanner, et al.
Deleted Journal (2025) Vol. 66, Iss. 3, pp. 331-337
Open Access
Update on vaccines against respiratory syncytial virus (RSV): A narrative review
José Gutierrez-Rodriguez, Jaime Rodríguez-Salazar, Francisco José Tarazona‐Santabalbina
Revista Española de Geriatría y Gerontología (2025) Vol. 60, Iss. 2, pp. 101630-101630
Closed Access
Adult Vaccine Coadministration Is Safe, Effective, and Acceptable: Results of a Survey of the Literature
Litjen Tan, Dana Trevas, Ann R. Falsey
Influenza and Other Respiratory Viruses (2025) Vol. 19, Iss. 3
Open Access
Viral community-acquired pneumonia: What’s new since COVID-19 emerged?
Catia Cillóniz, Alejandro J. Videla, Laura Pulido, et al.
Expert Review of Respiratory Medicine (2025)
Closed Access
Phase 3 Study Assessing Lot-to-lot Consistency of RSVPreF3 Vaccine and its Immune Response, Safety, and Reactogenicity When Co-administered with FLU-D-QIV
Nnenna Chime, Bruno Anspach, Vishal Jain, et al.
The Journal of Infectious Diseases (2024)
Open Access | Times Cited: 1
We Have Effective Respiratory Syncytial Virus Vaccines to Prevent Disease in Adults: What Else Do We Need to Know About How to Use Them?
Angela R. Branche
Clinical Infectious Diseases (2024) Vol. 79, Iss. 4, pp. 1099-1101
Closed Access
Cost-effectiveness of the adjuvanted RSVPreF3 vaccine among adults aged ≥60 years in the United States
Elizabeth M. La, James E. Graham, David Singer, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access
Schutzimpfungen bei CKD
Bernd Hohenstein, Thorsten Feldkamp, Matthias Girndt
Deleted Journal (2024) Vol. 19, Iss. 6, pp. 377-382
Closed Access

Giovanna Elisa Calabrò, Caterina Rizzo, Alexander Domnich, et al.
PubMed (2024) Vol. 65, Iss. 2 Suppl 1, pp. E1-E159
Closed Access
Vaccine and therapeutic agents against the respiratory syncytial virus: resolved and unresolved issue
Qianqian Li, Huan Li, Zhihua Li, et al.
MedComm (2024) Vol. 5, Iss. 12
Open Access
Respiratory Syncytial Virus: A WAidid Consensus Document on New Preventive Options
Matteo Riccò, Bahaa Abu-Raya, Giancarlo Icardi, et al.
Vaccines (2024) Vol. 12, Iss. 12, pp. 1317-1317
Open Access
Page 1

Scroll to top